Oxfam says Moderna hid vaccine dispute from investors

Oxfam America has filed a complaint with the US Securities and Exchange Commission (SEC) claiming that Moderna failed to inform investors that it was in a dispute with the National Institutes of Health over a COVID–19 vaccine patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Moderna in dispute with US govt over COVID-19 vaccine inventors

11 November 2021 Moderna is facing accusations from the US National Institute of Health that it failed to give due recognition to three scientists as inventors on its COVID-19 vaccine application.

Big Pharma

Dems pressure Biden to share Moderna vaccine tech

14 October 2021 A group of 12 Democratic Party members, including Senator Elizabeth Warren, have co-signed a letter calling for the Biden administration to share Moderna’s vaccine technology.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Oxfam says Moderna hid vaccine dispute from investors

More on this story

Editor's picks

Editor's picks

More features